Rhythm Pharmaceuticals met phase 3 endpoint for treating hypothalamic obesity, with regulatory submissions planned for 2025.

A Redditor shared that international students in New Zealand face significant challenges, including a lack of support from ...

Sangamo Therapeutics, Inc.'s $18M Eli Lilly deal boosts CNS genomic medicines. Fabry gene therapy data in 2025 is key for ...

Researchers sought to evaluate differences in ctDNA profiles, use of targeted treatments, and overall survival between Black and White patients with metastatic breast cancer.